Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | MicrobiomeTrials← Back to trialsNCT04345601
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-02-12Est. Completion: 2023-01-10
Enrollment target: 28 participants Locations- Houston Methodist Hospital, Houston, Texas, United States
Other microbiome trials you might be interested in
SARS-CoV-2
The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized a…
Coral Gables, United StatesEst. completion Jun 30, 2028
Anogenital HerpesCOVID-19Herpes Labialis
Background:
\- Viral infections are an important cause of illness and death in hospitalized patients as well as outpati…
Bethesda, United States
Phase 2
TERMINATED
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a d…
Fresno, United StatesCompleted Jul 22, 2024